Objective: Drug induced liver injury is an associated adverse effect seen with most of the drugs and the most common cause for a drug to be withdrawn from the market. First line antituberculosis drugs (ATT) are one of them. Anti-tuberculosis drugs are effective to provide complete cure from Mycobacterium tubercle but drug induced hepatotoxicity is one of the frequent and potentially serious adverse effect associated which may lead to therapy discontinuation. The Anti-tuberculosis treatment regimen must be discontinued once liver injury occurs, which may result in TB relapse and or drug resistance and or TB-related death. Thus study was planned to evaluate the hypothesis “Hepatoprotective activity of Rudanti (Capparis moonii Wight) in ATT induced Hepato-toxicity in wistar rats. Material and Methods: 24 healthy albino wistar rats was divided in 4 groups. Group A (Normal Control): 6 Healthy wistar albino rats had received distilled water 5 ml/kg P.O/day. Group B (Negative control): 6 hepato-toxicity induced wistar albino rats had received distilled water 5 ml/kg P.O/day. Group C (test Group): 6 hepato-toxicity induced wistar albino rats had received Capparis moonii 400 mg/kg/ P.O/day for 60 days. Group D (Standard Group): 6 hepato-toxicity induced wistar albino rats had received Silymarin 200 mg/kg / P.O/day for 60 days. Results: After 60 days of treatment the liver function biomarker showed significant increase in the ALT, AST, ALP, Total Bilirubin levels in ATT treated groups as compared to control group with normal animals. Whereas, in group C (Rudanti) significant reduction noted proves the hepato-protective activity of test drug comparable to standard (group D Silymarine) comparator evident for its hepato-protective activity